Scarica l'app Stockscreener
4.26
2.29%
-0.10
Pre-mercato:
4.25
-0.010
-0.23%
Precedente Chiudi:
$4.36
Aprire:
$4.23
Volume 24 ore:
611.80K
Relative Volume:
5.18
Capitalizzazione di mercato:
$337.45M
Reddito:
-
Utile/perdita netta:
$-31.64M
Rapporto P/E:
-10.08
EPS:
-0.4226
Flusso di cassa netto:
$-13.98M
1 W Prestazione:
+16.39%
1M Prestazione:
+2.40%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.05
$4.30
Intervallo di 1 settimana:
$3.51
$4.40
Portata 52W:
$3.51
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Nome
Nervgen Pharma Corp
Settore
Industria
Telefono
-
Indirizzo
-
Compare NGEN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
4.26 | 337.45M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Nervgen Pharma Corp Borsa (NGEN) Ultime notizie
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight - The Manila Times
NervGen Pharma Corp. Stock Chart | NASDAQ: NGEN Stock Price - Bitget
This analyst loves NervGen Pharma - cantechletter.com
NervGen appoints regulatory and patient advocacy executives - Investing.com
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions - TipRanks
NervGen Pharma reports full year 2025 financial results and provides business updates - MarketScreener
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates - Bitget
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Spinal Cord Injury Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler - Barchart
NervGen Pharma Corp.(TSXV: NGEN) dropped from S&P/TSX Venture Composite Index - marketscreener.com
NervGen Pharma (NGEN.US) Income Statements, Balance Sheet & Cashflow - Longbridge
NervGen Pharma Stock Quote, Share Price, News and Analysis - Longbridge
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) (NASDAQ:NGEN) - Seeking Alpha
NGEN.CA Stock Price, Quote & Chart | NERVGEN PHARMA CORP (TSX-V:NGEN) - ChartMill
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - Sahm
NervGen Pharma to delist shares from TSX - TipRanks
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exc - GuruFocus
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances - TipRanks
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Nigeria
NervGen Pharma proposes amendment to warrant terms - MSN
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy - geneonline.com
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NervGen Pharma (NGEN) Stock Analysis Report | Financials & Insights - Benzinga Japan
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
How NervGen Pharma Corp. (9UA) stock reacts to weak economy2025 Dividend Review & Low Risk High Win Rate Picks - mfd.ru
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - The Manila Times
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Nigeria
Why NervGen Pharma Corp. (9UA) stock stays on buy listsInsider Selling & High Conviction Investment Ideas - mfd.ru
Why NervGen Pharma Corp. (9UA) stock could be next leader2025 Price Momentum & Growth Focused Stock Pick Reports - mfd.ru
NervGen Pharma to Present at Unite2Fight Paralysis 20th Annual Science and Advocacy Symposium - marketscreener.com
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - The Manila Times
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
Nervgen Pharma Corp Azioni (NGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):